May 4, 2020 Locust Valley, New York
STANDARD VAPE ANNOUNCES INITIAL MEMBERS OF SCIENTIFIC ADVISORY BOARD FOR SUBSIDIARY NEO VIRUCIDE, INC.
STANDARD VAPE CORPORATION (SVAP-OTC PINK) announced today that it has signed agreements with four highly respected personages to commence the joint Scientific Advisory Board with both Neo Virucide, Inc. (“NVI”) and NMB Therapeutics, Inc. (“NMB”) a related party. On April 14, 2020, SVAP acquired newly incorporated NVI that owns an exclusive worldwide license on the use of a proprietary nanoparticle NanoNOx™ for treatment of microbial and viral infections. In a sense NanoNOx™ seeks to fulfill President Trump’s stated desire to use a disinfecting agent as a treatment for COVID-19. NanoNOx™ has been shown to kill a wide spectrum of microbial and viral agents in vitro, thus being a probably biologically safe inhalable disinfecting agent. In addition, NanoNOx™ is thought to have anti-inflammatory effects, causes vasodilation, and provides additional oxygen. The Scientific Advisory Board (SAB) Members are:
Makarand Jawadekar, Ph.D., is currently an independent pharma professional. He worked for Pfizer, Inc. for 28 years. In 2010 he was Director, Portfolio Management for Pfizer. During his career with Pfizer he was responsible, at various times, for external drug delivery technology assessment, created and cultivated external partnerships and alliances for drug delivery technologies, among others. He is active on the Strategic and Scientific Advisory Boards of several companies and the Task Force in Washington DC on COVID 19.
Joshua Nosanchuk, M.D. is currently Senior Associate Dean for Medical Education at Albert Einstein College of Medicine. He is a professor in the Department of Medicine (infectious diseases) and the Department of Microbiology and Immunology. His areas of research include medical education, fungal pathogenesis, host-pathogen biology, regenerative medicine and innovative therapeutics.
Jimmy K. Lee, M.D., is Director of Cornea and Refractive Surgery at Montefiore Medical Center and Associate Professor of Ophthalmology and Visual Sciences at Albert Einstein College of Medicine, Bronx, New York. Dr. Lee is working with NMB to conduct in vitro research utilizing NanoNOx™ which is thought to be beneficial in treating infections of the cornea and as a cleansing agent for contact lenses.
Karen Kingston, B.B.A., Principal, Activiis where she serves as Marketing and Public Relations Strategist for healthcare companies, performs executive coaching for Fortune 500 clients, technical and creative writer responsible for production of hundreds of marketing, sales and Public Relations materials in various media.
The diverse talents and skills sets of these individual, along with others in Neo Virucide will greatly facilitate the development of NanoNOx™ as a medical treatment for microbial and viral diseases in the coming months and years. Each Member receives 50,000 shares of the common stock of Neo Virucide and 50,000 shares of NMB Therapeutics for each year they serve on the SAB.
About Neo Virucide, Inc.
Formed as a subsidiary of SVAP in April 2020 it holds the worldwide marketing rights to NanoNOx™, the proprietary nanoparticle upon which a United States Provisional Patent Application had been filed in November, 2019 by NMB. While NanoNOx™ has several uses, NVI’s present focus is assisting NMB in gaining permission from the FDA or foreign agencies or testing locations to test NanoNOx™ in human trials as a means of delivering nitric oxide into deep lung tissue for the purpose of treating COVID-19.
WARNING: Please note: THE USE OF HOUSEHOLD DISINFECTANTS BY INGESTION OR INJECTION WILL BE FATAL. NanoNOx™ may, once tested and approved for treating COVID-19, or other infections, if such testing occurs and if approved by the FDA in a New Drug Application, a process that may take years and for which no assurance can be given of success, increase vasodilation, and possibly attack microbes and viruses in patients. Neither Neo Virucide nor Standard Vape Corporation (SVAP) claims that any use of NanoNOx™ will be approved for use in the United States, nor in any other country, WITHIN ANY PREDICTABLE TIME FRAME.
About Standard Vape Corporation
Standard Vape Corporation is engaged in the development of a unique vaping technology. Through is controlled subsidiary, Nano Vape Corporation, Standard Vape controls what it believes to be the only vaping system that does not require heating of the vaping fluid to form a vapor. PCT applications have been filed on that system and additional applications are being drafted by Nano and a related party aimed toward a new vaping fluid. More information can be found at www.standard-vape.com.
Legal Disclaimer
This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.
Contact Information
Roger Fidler
Legal Counsel to SVAP
NVI President
(201) 220-8734
rfidler0099@aol.com
Brinsley Holman
+44 (0)207 464 4090
brinsley.holman@kbrl.co.uk